Skip to main content
OpenTrials
Completed

NCT Number: NCT01534507

Small and Large Bowel Transit Tests Using MRI (Study 1)

Irritable bowel syndrome, (IBS) is a common functional disorder of the gut that can be quite disabling to patients. The most common symptoms of IBS are abdominal pain or discomfort along with erratic changes in bowel habit of diarrhoea, constipation or a mixture of the two (referred to as IBS subtypes). Despite much research efforts to further understand the pathophysiology of IBS; as yet no specific biomarkers/definitive measurements have been identified that can be use to aid the diagnosis and reduce the need for unnecessary, unpleasant and expensive tests.

Evidence shows that anxiety plays a part in IBS and can speed up transit time in the small bowel. In this study, the investigators hypothesise that since anxiety is a common feature of IBS, then fast small bowel transit is likely to be found in all subtypes of IBS and the difference in stool frequency and consistency in IBS subgroups are therefore likely to reflect differences in colonic function. The investigator wish to test this by measuring both small and large bowel transit times using Magnetic Resonance Imaging (MRI) and validate the results of the MRI with two methods currently used in clinical practice -The previously validated lactose-C13 Ureide breath test (for small bowel transit) and the standard radio-opaque pellet method to assess the whole gut transit (WGT) time.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Nottingham

Nottingham, Notts, NG7 2UH, United Kingdom

About this study

The investigator has 2 main parts in this study i.e. Study 1 and Study 2.

As part of study 1, the investigator would like to recruit up to 5 healthy volunteers as a pilot study to optimise measurement and analysis of the Lactose-C13 Ureide breath test along with MRI scannings at regular intervals.

Following from this, the investigator would like assess the feasibility and reproducibility of using MRI imaging to assess gastrointestinal transit. The investigator would like to recruit 21 healthy volunteers to measure orocaecal transit time (OCTT) and whole gut transit(WGT)using the conventional method of Lactose-C13 Ureide breath test for OCTT and the Metcalf method using standard radio-opaque pellet method for WGT and compare them will MRI imaging. Once this has been analysed and the best method for each OCTT and WGT have been decided, these methods would be applied in Study 2.

In study 2, the investigator would like to recruit 30 healthy volunteers, 30 patients with diarrhoea predominantly Irritable Bowel Syndrome, 30 patients with constipation predominantly Irritable Bowel Syndrome and 30 patients with Mixed irritable Bowel Syndrome. The best methods from study 1 for OCTT and WGT will be applied here to assess gastrointestinal transit on these subjects. Based on the first study, the best method to assess OCTT is the Lactose-C13 Ureide breath test and for the WGT, the best method is the MRI marker capsules. Participants will need to fill in questionnaires to assess their stress levels and to fill in symptom questionnaires during the study day.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Study 1

Inclusion criteria

  • 26 healthy volunteer
  • Age 18-75 years old
  • Non-smoker
  • Able to give informed consent

Exclusion criteria

  • Lactose intolerant
  • Any history of gastrointestinal surgery on the small bowel (excluding appendicectomy)
  • Pregnancy
  • contraindications for MRI scanning i.e. metallic implants, pacemakers, history of metallic foreign body in eye(s) and penetrating eye injury alcohol dependence
  • serious concomitant illness as judged by the investigators
  • use of drugs known to alter GI motility including opiates, anti-depressants, selective serotonin reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, phenothiazines, benzodiazepines, calcium channel antagonists during or in the 2 weeks prior to the test
  • inability to lie flat or exceed scanner limits of weight >120kg or abdominal circumference >99cm ; BMI <18 and >30 kg/m2
  • Poor command of English language
  • Participation of any medical trials for the past 3 months

Study 2:

120 participants consisting of: 30 patients with diarrhoea predominant IBS according to Rome III criteria 30 patients with constipation predominant IBS according to Rome III criteria 30 patients with mixed type IBS according to Rome III criteria 30 healthy volunteers age and sex matched controls

Inclusion criteria

  • Meet the Rome III criteria and the IBS subtypes
  • Age 18-75 years old
  • Able to give informed consent
  • Subjects will undergo a limited screening medical. They will also complete a MRI - safety questionnaire and be given an information sheet
  • Able to give informed consent
  • Subjects will undergo screening medical questionnaire. They will also complete a MRI safety questionnaire and be given an information sheet

Exclusion criteria

  • Any history of gastrointestinal surgery on the small bowel (excluding appendicectomy)
  • Pregnancy
  • contraindications for MRI scanning i.e. metallic implants, pacemakers, history of metallic foreign body in eye(s) and penetrating eye injury
  • alcohol dependence
  • serious concomitant illness as judged by the investigators
  • use of drugs known to alter GI motility including opiates, , monoamine oxidase inhibitors, phenothiazines, benzodiazepines, calcium channel antagonists during or in the 2 weeks prior to the test
  • Selective serotonin reuptake inhibitors or low dose tricyclic antidepressants will be recorded but will not be an exclusion
  • No recent antibiotic treatment past 2 weeks
  • inability to lie flat or exceed scanner limits of weight >120kg or abdominal circumference >99cm; BMI <18 and >30 kg/m2
  • Poor command of English language
  • Participation of any medical trials for the past 3 months

Treatment and study plan

Primary outcomes

  1. Study 1:Correlation between mean orocaecal transit time as assessed by MRI and lactose C13-ureide

    Time frame: 9 hours

    MRI:Orocaecal transit time (OCTT) can be measured by the first scan showing arrival of the head of a meal in the ascending colon Lactose C13-Ureide breath test:Orocaecal transit time will be taken as the time at which a significant increase from background in breath 13C was seen.

  2. Study 1: Correlation between colonic transit as assessed by from the geometric centre of the PTFE capsule at time 24 and 48 hours and Metcalf Radio-opaque marker method

    Time frame: 72 hours

    Colonic transit using MRI will be measure by assessing the geometric centre position in colon/small bowel.

    Whole gut transit time using the Metcalf method of Radio-opaque Marker method would be estimated by counting the number of pellets remaining in the colon in an abdominal x-ray taken in day 4 * 1.2

  3. Study 2: Fasting small bowel water content

    Time frame: 1 hour

    Fasting small bowel water content (SBWC) in the 3 subgroups of Irritable Bowel Syndrome (IBS) compared to healthy controls

Secondary outcomes

  1. Study 1:To assess reproducibility of the using MRI for orocaecal transit time and colonic transit time

    Time frame: 21 days

    In study 1, the orocaecal transit time and colonic transit time would be repeated twice with a week break in between to assess reproducibility of the MRI.

  2. Study 2: Orocaecal transit time using lactose C13-ureide

    Time frame: 9 hours

    Orocaecal transit time in the 3 subgroups of IBS versus healthy control using the best method from study 1 which is the lactose C13-Ureide breath test

  3. Study 2: Area under the curve (AUC) post prandial SBWC

    Time frame: 9 hours

  4. Study 2: Ascending colon water content (ACWC) and colonic water index (CWI)

    Time frame: 9 hours

  5. Study 2: Colonic volumes both fasting and post prandial (divided into ascending transverse and descending colon)

    Time frame: 9 hours

  6. Study 2: Whole gut transit time assess by MRI marker capsule from study 1

    Time frame: 24 hours

    The best method to assess the whole gut transit time based on study 1 was the use of the MRI marker capsule at time 24hours

  7. Study 2: Correlation between the Hospital Anxiety & Depression Scale (HADS) and other measures of anxiety and stress score and (a) Oro-caecal transit time and (b)whoe gut transit time

    Time frame: 9hours

Sponsors and collaborators

Lead sponsor

University of Nottingham

Other

Registry information

Official study title

Optimising Measurement of Small and Large Bowel Transit During MRI Scanning and Characterising IBS Subtypes and Their Response to Stress Using MRI (Study 1)

Important dates

Study start
2011
Primary completion
2014
Study completion
2014
First posted
Feb 16, 2012
Registry last updated
Aug 13, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.